Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
The closing price of Regenxbio Inc (NASDAQ: RGNX) was $5.89 for the day, up 8.87% from the previous closing price of $5.41. In other words, the price has increased by $8.87 from its previous closing price. On the day, 1.22 million shares were traded. RGNX stock price reached its highest trading level at $5.95 during the session, while it also had its lowest trading level at $5.16.
Ratios:
Our analysis of RGNX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.69 and its Current Ratio is at 2.69. In the meantime, Its Debt-to-Equity ratio is 0.55 whereas as Long-Term Debt/Eq ratio is at 0.38.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on February 11, 2025, Downgraded its rating to Neutral and sets its target price to $14 from $38 previously.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 30 ’24 when VITTAL VASISTA bought 20,041 shares for $7.41 per share.
KARABELAS ARGERIS N sold 10,000 shares of RGNX for $101,052 on Oct 01 ’24. The Director now owns 11,286 shares after completing the transaction at $10.11 per share. On Sep 03 ’24, another insider, KARABELAS ARGERIS N, who serves as the Director of the company, sold 10,000 shares for $11.56 each. As a result, the insider received 115,588 and left with 11,286 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RGNX now has a Market Capitalization of 295188544 and an Enterprise Value of 202040352. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.54 while its Price-to-Book (P/B) ratio in mrq is 1.12. Its current Enterprise Value per Revenue stands at 2.425 whereas that against EBITDA is -0.94.
Stock Price History:
The Beta on a monthly basis for RGNX is 1.25, which has changed by -0.67314094 over the last 52 weeks, in comparison to a change of 0.059571505 over the same period for the S&P500. Over the past 52 weeks, RGNX has reached a high of $19.38, while it has fallen to a 52-week low of $5.03. The 50-Day Moving Average of the stock is -17.19%, while the 200-Day Moving Average is calculated to be -38.56%.
Shares Statistics:
RGNX traded an average of 983.39K shares per day over the past three months and 1178390 shares per day over the past ten days. A total of 49.55M shares are outstanding, with a floating share count of 45.21M. Insiders hold about 9.79% of the company’s shares, while institutions hold 86.24% stake in the company. Shares short for RGNX as of 1743379200 were 5219257 with a Short Ratio of 5.31, compared to 1740700800 on 6280862. Therefore, it implies a Short% of Shares Outstanding of 5219257 and a Short% of Float of 13.58.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
